Cipla

23rd July, 2026

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Symbol: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: <u>Investor Presentation</u>

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation dated 23rd July, 2026.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Cipla Limited**

RAJENDRA CHOPRA
Digitally signed by RAJENDRA CHOPRA
Date: 2026.07.23 12:34:10 +05'30'

Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Simona Dsouza

Cipla

Investor Presentation

Q1FY27

23-07-2026

DISCLAIMER

Cipla

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

Delivered the Highest Q1 Revenue

	Revenue	EBITDA	PAT
Q1FY27	INR 7,119 Cr	INR 1,192 Cr (16.7% Margin)	INR 789 Cr (11.1% Margin)

Business Performance Snapshot

	One India	North America	One Africa	Emerging Markets & Europe
Q1FY27	INR 3,452 Cr ↑ 12% (YoY)	$ 162 Mn	$ 103 Mn ↑ 1% (YoY)	$ 106 Mn ↑ 5% (YoY)
	Highest-ever quarterly revenue	*Launched first AB-rated gVentolin with CGT*	*SA private growing faster than the market[1]*	*Continued growth trajectory*

1. Market data as per IQVIA MAT May'26

Financial Performance : Q1FY27

Cipla

Revenues INR 7,119 Cr

EBITDA 1,192 Cr

Revenue[1] Break-up



Q1FY27 (Consolidated)

	Q1FY27 (INR Cr)	Q1FY26 (INR Cr)
Total Revenue from Operations	**7,119**	**6,957**
EBITDA	1,192	1,778
EBITDA %	***16.7%***	***25.6%***
PAT	789	1,298
PAT %	***11.1%***	***18.7%***

R&D[2] INR 486 Cr | 6.8% of revenue

1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation

One India[1] : Building a Sustainable Legacy for Enduring Growth

Cipla

Highest-ever quarterly revenue of INR 3,452 Cr

Branded Prescription

- Cipla maintained #2 rank in overall chronic with chronic mix[2] improved to 60.4%
- Continued portfolio expansion with the launch of Yurpeak, Duolin Syncrobreathe, Doloneuron, and Nasowash
- Double-digit growth[2] in chronic therapies like Respiratory, Urology, Anti-diabetes and Cardiac

Trade Generics

- Posted steady growth supported by robust performance across key categories
- 4 Brands with TTM revenue of > INR 100 Cr and 3 Brands with TTM revenue of INR 50 Cr to INR 100 Cr
- 3 new launches in Q1FY27

Consumer Health

- Anchor and transitioned brands continuing to grow bigger
- Sustained EBITDA margin trajectory
- Nicotex, Omnigel and Cipladine maintained their leadership positions in the market

1. One India includes Rx, Gx and CHL | 2. Market data as per IQVIA MAT June'26

India Rx : Strengthening Our Journey with Strategic Therapeutic Focus

Cipla

Steady Uptake in Key Therapies[1] Growth (%)		Rank
Respiratory	13%	1st
Urology	10%	2nd
Anti-diabetic	26%	11th
Cardiac	14%	7th
Dermatology	11%	11th

Largest pharma company by volume (units) in market[1]

Our in-house brand franchise, Dytor[1], has scaled to over INR 700 Cr+

Delivered market[2] growth of 15.4%, 183 bps higher than IPM

Key Market Highlights

1000+ Cr Foracort

Biggest Respiratory Brand in IPM[1]

23 Brands

IPM[1] Brands in Top 300 ranks

33 Brands

IPM[1] Brands with revenue > INR 100 Cr

7 Therapies

With IPM[1] Top 5 ranks

1. Market data as per IQVIA MAT June'26 | 2. Market data as per IQVIA, Quarter ended June 2026

Recent Launches Demonstrate Strong Early Momentum Across Priority Therapies

Breath-actuated metered-dose inhaler used to manage and treat symptoms of COPD & Asthma

Neuro-pain brand with an extended-release offering aimed at improving adherence in chronic pain management



Supportive care brand with a differentiated combination of Hyaluronic Acid and N-Acetyl L-Cysteine

Oral JAK inhibitor for chronic inflammatory and autoimmune conditions

Upper-respiratory care brand with a saline-based nasal hygiene solution for congestion & dryness

Anti-allergy respiratory portfolio with Bilastine + Montelukast for allergic rhinitis and associated nasal symptoms

Neuro-supportive nutrition with a differentiated combination of PEA, Acetyl L-Carnitine, Boscurin and Uridine Monophosphate

Anti-diabetic brand in Type 2 diabetes, targeting improved glycaemic control

Q1 FY27 : Global Consumer Wellness Franchise

Cipla

One India

prolyte ORS — Hydration

OMNIGEL — Pain Relief

nicotex — Smoking Cessation

CIPLADINE — Skin Infection

cofsils — Cold and Cough

Consumer Brands in One India

Revenue : INR 481 Cr

+

Consumer Brands in South Africa

Revenue : ZAR 405 Mn

One Africa

CORYX — Cold and Cough

BRONCOL — Cold and Cough

Cipla Actin — Respi OTC

IBUMAX — Cold and Flu

ASTHAVENT Metered-dose inhaler — Respi OTC

Note:- Above numbers exclude sales of wellness brands through prescription channel

North America : Adapting to Evolving Business Dynamics

Key Business Highlights

- gProventil ranked No. 1 with total market[1] share at 21% (50 million+ inhaler units supplied to the U.S. market cumulatively)
- Launched gVentolin in the U.S. market during the quarter, with initial shipments executed and supply ramp-up planned over the coming quarters

Recent New Launches

gVentolin



Nintedanib

Dapagliflozin

Liraglutide

1. Market data as per IQVIA week ending 26th June'26 (No. 1 rank in overall U.S. Albuterol MDI market)

ANDA & NDA Portfolio & Pipeline (As on 30th June 2026)

Cipla



186 Approved ANDAs & NDAs + **44** Tentatively Approved ANDAs & NDAs + **48** Under Approval ANDAs & NDAs = **278** Total ANDAs & NDAs

1. PEPFAR approved ANDAs can be commercialised in US

One Africa[1] : South Africa Private Growing Faster than the Market



SA Key Highlights[2]

- Healthy performance across key therapies like Respiratory, CNS and Alimentary TR & Metabolism.
- 10 brands with MAT market revenue > 100 Mn ZAR
- Highest number of brands in top 30 (6), top 50 (11) and top 100 (20) within generics segment
- Private business revenue of ZAR 906 Mn for Q1FY27

Market Segment [2]	Rank	Share	Cipla Growth	Market Growth
South Africa Prescription	2	8.8%	9.8%	6.9%
South Africa OTC	3	7.8%	0.6%	3.5%
South Africa Overall	3	8.5%	6.5%	5.7%

Growth 1.2X
Faster growth than market for private business

4 new launches
Across multiple therapies in Q1 FY27

1. One Africa - South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Market data as per IQVIA MAT May'26

Progress on ESG goals (India Manufacturing Operations) : Q1FY27

Cipla

	Aspects	Goals FY 2029-30	Progress
Environment	Renewable Electricity Share	80% renewable electricity share for India manufacturing	57%*
	GHG Emissions (Scope 1 & 2)	30% absolute reduction (Scope 1-Energy based & Scope-2) from baseline of FY2023-24 for Global Cipla	21%
		Build capacity infrastructure for green propellants used in MDI	Ongoing pilot project
	Water Neutrality	Water Neutral for India manufacturing	Achieved 2.6x water positivity FY26 Next Certification - Mar'27
	Zero Waste to Landfill	Maintain ZWL status for Cipla India and expand coverage for ZWL to overseas sites for USA and One Africa	CMM Certified- July'26; India Manufacturing Certification - Mar'27
Social	AMR	One antibiotic product per Cipla India site certified as per AMR manufacturing standard	Certification for 2 Sites - Mar'27
	Occupational Health and Safety	Zero fatality in manufacturing operations	0
	DEI	Representation of women in Cipla Leadership Group at 20% or above from a baseline year of FY25	14.8%
Governance	Responsible Procurement	Minimum 80% of critical Indian suppliers to comply with Cipla ESG framework	Preparation of supplier assessment ESG framework

Achievement

CIPLA MEDPRO MANUFACTURING PTY LTD, South Africa **achieved the Green Building Council South Africa (GBCSA) Net Zero Waste Certification.**

*With purchased I-RECs till Apr'26

Consolidated Profit and Loss Statement Summary

INR Cr

Particulars	Q1FY27	Q1FY26
Revenue from sale of products	7,077	6,837
Other operating income	42	120
Income from operations	**7,119**	**6,957**
Material cost	2,667	2,171
Employee benefits expense	1,497	1,312
Other expenses	1,762	1,696
Total expenses	**5,927**	**5,179**
Finance costs	17	14
Depreciation, impairment and amortisation expense	304	253
Other income	211	259
Profit before tax	**1,082**	**1,770**
Tax expenses	295	478
Share of associate	-2	-0
Profit for the period	**786**	**1,292**
Non-controlling interest	-3	-6
Profit for the period attributable to shareholders	**789**	**1,298**

Note : Figures have been rounded-off

Consolidated Balance Sheet

INR Cr

Key Balance Sheet Items	Jun-26	Jun-25
Equity	34,443	32,665
Total Debt#	600	459
Inventory	6,714	6,091
Cash and Cash Equivalents*	10,094	10,838
Trade Receivables	5,948	6,254
Trade Payables	3,446	3,093
Net Tangible Assets	7,889	6,669
Goodwill and Intangibles	6,928	5,138

#Total debt includes lease liabilities and borrowings | *Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances | Figures have been rounded-off

Cipla

Thank You

Registered Office :

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

Diksha Maheshwari

Investor.Relations@cipla.com

For more information, please visit

www.cipla.com